Dimensional Fund Advisors LP Has $1.42 Million Stake in Nkarta, Inc. (NASDAQ:NKTX)

Dimensional Fund Advisors LP increased its position in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 101.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 569,357 shares of the company's stock after buying an additional 286,181 shares during the quarter. Dimensional Fund Advisors LP owned 0.81% of Nkarta worth $1,417,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NKTX. Invesco Ltd. acquired a new position in Nkarta during the fourth quarter worth $30,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Nkarta in the fourth quarter valued at $31,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Nkarta in the fourth quarter valued at about $37,000. Catalina Capital Group LLC lifted its position in Nkarta by 57.5% during the 4th quarter. Catalina Capital Group LLC now owns 18,818 shares of the company's stock worth $47,000 after buying an additional 6,867 shares in the last quarter. Finally, Sei Investments Co. bought a new stake in Nkarta during the 4th quarter worth about $57,000. 80.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Stifel Nicolaus decreased their price objective on Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 27th. William Blair reissued a "market perform" rating on shares of Nkarta in a research note on Thursday. Needham & Company LLC dropped their target price on shares of Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Thursday. Finally, HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Nkarta in a report on Thursday, March 27th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $14.67.

Nkarta Stock Down 2.3%

Shares of NKTX traded down $0.04 during mid-day trading on Monday, hitting $1.70. 566,240 shares of the company's stock were exchanged, compared to its average volume of 1,066,209. Nkarta, Inc. has a 52 week low of $1.31 and a 52 week high of $8.23. The stock's 50-day simple moving average is $1.79 and its 200-day simple moving average is $2.19. The firm has a market cap of $120.63 million, a price-to-earnings ratio of -0.90 and a beta of 0.81.

Nkarta (NASDAQ:NKTX - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.01. Analysts forecast that Nkarta, Inc. will post -1.7 earnings per share for the current fiscal year.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.